This statistic shows percentage of U.S. patients treated with PD-1 and PD-L1 checkpoint inhibitors in 2018, by tumor type. According to the data, 52.4 percent of patients treated with PD-1 and PD-L1 checkpoint inhibitors were for lung tumors.
Percentage of U.S. patients treated with PD-1 and PD-L1 checkpoint inhibitors in 2017, by tumor type
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
IQVIA. (May 28, 2018). Percentage of U.S. patients treated with PD-1 and PD-L1 checkpoint inhibitors in 2017, by tumor type [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/883506/checkpoint-inhibitors-us-usage-by-tumor-type/
IQVIA. "Percentage of U.S. patients treated with PD-1 and PD-L1 checkpoint inhibitors in 2017, by tumor type." Chart. May 28, 2018. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/883506/checkpoint-inhibitors-us-usage-by-tumor-type/
IQVIA. (2018). Percentage of U.S. patients treated with PD-1 and PD-L1 checkpoint inhibitors in 2017, by tumor type. Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/883506/checkpoint-inhibitors-us-usage-by-tumor-type/
IQVIA. "Percentage of U.S. Patients Treated with Pd-1 and Pd-l1 Checkpoint Inhibitors in 2017, by Tumor Type." Statista, Statista Inc., 28 May 2018, https://www-statista-com.ezproxy.canberra.edu.au/statistics/883506/checkpoint-inhibitors-us-usage-by-tumor-type/
IQVIA, Percentage of U.S. patients treated with PD-1 and PD-L1 checkpoint inhibitors in 2017, by tumor type Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/883506/checkpoint-inhibitors-us-usage-by-tumor-type/ (last visited November 10, 2024)
Percentage of U.S. patients treated with PD-1 and PD-L1 checkpoint inhibitors in 2017, by tumor type [Graph], IQVIA, May 28, 2018. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/883506/checkpoint-inhibitors-us-usage-by-tumor-type/
